Hemostats Market

The market for Hemostats was estimated at $2.9 billion in 2024; it is anticipated to increase to $4.4 billion by 2030, with projections indicating growth to around $6.1 billion by 2035.

Report ID:DS1801621

Author:Debadatta Patel - Senior Consultant

Published Date:November 2025

Datatree

Life Science

Medical Device

Hemostats

Customization Available

Hemostats - 2024-2034

Market Outlook
Market Key Insights
Growth Opportunity
Market Dynamics
Application
Recent Development
Impact Analysis

Report Summary

Market Data

Methodology

Table of Contents

Report Summary

Market Data

Methodology

Table of Contents

Global Hemostats Market Outlook

Revenue, 2024

$2.9B

Forecast, 2034

$5.7B

CAGR, 2025 - 2034

6.9%

The Hemostats industry revenue is expected to be around $3.1 billion in 2025 and expected to showcase growth with 6.9% CAGR between 2025 and 2034. The hemostats industry is experiencing robust growth driven by the rising number of surgical procedures worldwide, particularly in orthopedic and general surgery, which together account for 54.1% of the market applications. Increasing procedural volumes, coupled with the growing complexity of surgeries, are fueling demand for advanced hemostatic solutions that can efficiently control bleeding. Technological advancements in hemostat formulations and delivery mechanisms have further strengthened the market, enabling surgeons to achieve faster blood coagulation, reduce operative time, and improve patient outcomes. Among these, oxidized regenerated cellulose (ORC) based hemostats have gained significant traction due to their superior performance, biocompatibility, and ease of use, with the market value for ORC-based products reaching $1.15 billion in 2024.

Hemostats are specialized surgical instruments designed to manage bleeding and facilitate safe, controlled surgical procedures. They function by promoting coagulation and effectively stopping blood flow, which is critical in minimizing intraoperative complications. The medical industry offers a wide range of hemostatic products tailored to specific surgical needs, including thrombin-based, gelatin-based, and oxidized regenerated cellulose-based hemostats. Each type is optimized for particular applications, ensuring reliable hemostasis in diverse operative environments. Continuous innovation in materials, absorbable formulations, and user-friendly designs is further enhancing their adoption across hospitals, surgical centers, and specialized clinics, positioning hemostats as essential tools in modern surgery.

Hemostats market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034 — Hemostats Market Outlook

Market Key Insights

The Hemostats market is projected to grow from $2.9 billion in 2024 to $5.7 billion in 2034. This represents a CAGR of 6.9%, reflecting rising demand across Orthopedic Surgery, General Surgery, and Cardiovascular Surgery.
Johnson & Johnson Services Inc., Baxter, and B. Braun SE are among the leading players in this market, shaping its competitive landscape.
The Hemostats market shows its largest customer base in the United States and Germany which will experience growth rates of 4.5% to 6.6% from 2024 to 2030.
It is predicted that Brazil, India and South Africa will experience the highest growth rates at 7.9% to 9.5% CAGR.
Transition like Advanced Bioactive Hemostat Adoption has greater influence in U.S. and Germany market's value chain; and is expected to add $169 million of additional value to Hemostats industry revenue by 2030.
The Hemostats market will experience $2.8 billion growth during 2024-2034 while General Surgery & Neurological Surgery Application manufacturers will dominate market expansion.
The Hemostats market will experience a 95% expansion from 2024 to 2034 because of rising surgical operations and improved hemostatic products and increasing use of minimally invasive surgical techniques.

Hemostats - Country Share Analysis

Opportunities in the Hemostats

The Combination Hemostats market will also expand at a 9.5% annual rate until 2030 when it reaches 0.77 billion. The product achieves fast blood clotting and supports tissue recovery which drives its market expansion. The advanced wound care market represents an unexplored opportunity because these hemostats show potential for treating chronic wounds and post surgical patients.

Growth Opportunities in North America and Europe

The North American market serves as a major region for hemostats because it has developed healthcare facilities and people widely accept new surgical techniques. The main use of hemostats in this market segment occurs during orthopedic surgical procedures because the aging population leads to more orthopedic conditions. The market competition becomes more intense because of Johnson & Johnson Services Inc. and Medtronic PLC but these companies create chances for strategic business alliances. The market expansion will become more successful through dedicated research of new hemostats and by developing marketing plans which demonstrate their safety and effectiveness in orthopedic surgical procedures.

The European market requires hemostats most urgently because cardiovascular diseases occur frequently throughout the region. The European market faces competition because Baxter and B. Braun SE operate within it. The need for fast and effective bleeding management during surgical procedures creates potential market expansion opportunities. A strategic business decision could involve developing hemostats which target cardiovascular surgical procedures. The market would expand when healthcare professionals understand the advantages of using modern hemostats during cardiovascular surgical procedures.

Market Dynamics and Supply Chain

Driver: Increasing Surgical Procedures and Advancements in Hemostatic Agents

The worldwide hemostats market shows rising expansion because surgical procedures continue to increase globally. The market demand for hemostats directly follows the rising number of surgical operations which include cardiovascular procedures and orthopedic surgeries and general surgical procedures. The procedures require hemostats to stop bleeding and start clotting because they produce substantial blood loss. The market expansion results from technological improvements that have also occurred in hemostatic agent development. The surgical field has also experienced a transformation because of new hemostatic products which offer enhanced performance and safety and better biocompatibility. The development of new hemostatic products has also resulted in the creation of bleeding control solutions which work quickly to minimize surgical complications and enhance patient results.

The medical field has also adopted minimally invasive surgeries because these procedures offer patients several advantages including minimized pain and smaller scars and shorter recovery periods and decreased chances of developing infections. The success of minimally invasive surgeries also depends on hemostats because they enable surgeons to maintain a bloodless operating area. The increasing use of minimally invasive surgery in gynecology and urology and gastrointestinal surgery has also created substantial market demand for effective and dependable hemostats. The hemostats market will also experience increased expansion because minimally invasive surgery remains a popular medical practice.

Restraint: Regulatory Challenges and Stringent Approval Processes

The worldwide hemostats market encounters major obstacles because numerous nations enforce strict regulatory systems which extend their approval procedures. The approval process for new products becomes longer because regulatory bodies demand complex clinical testing and extensive documentation. The lengthy and costly approval process for new products could delay their market entry which would limit market expansion.

Opportunity: Increasing demand for Oxidized Regenerated Cellulose Based Hemostats in the medical industry and Growing adoption of Thrombin Based Hemostats in developing countries

The medical field experiences rising demand for Oxidized Regenerated Cellulose Based Hemostats. The market for these hemostats will achieve 1.67 billion in revenue by 2030 while showing a 6.3% annual growth rate from 2025 to 2030. The products success in surgical bleeding control and its body friendly properties and tissue absorbing characteristics drive its market expansion. The product shows promise for additional applications in complicated surgical operations and emergency trauma situations.

The market for Thrombin Based Hemostats in developing countries shows increasing demand because it will reach 0.83 billion by 2030 with a 7.1% annual growth rate. The rising number of surgical operations together with better healthcare infrastructure development creates market expansion. The company achieves this through strategic partnerships with healthcare organizations in these areas to boost product acceptance.

Challenge: High Costs and Limited Accessibility in Developing Regions

The expensive nature of advanced hemostats together with their restricted availability in developing areas creates a significant market challenge. The high prices of advanced hemostats prevent healthcare facilities in developing regions from acquiring these products which blocks market expansion. The market growth faces obstacles because healthcare facilities in these regions do not only have enough trained staff to operate these hemostats properly.

Supply Chain Landscape

Raw Material Suppliers

Johnson & JohnsonBaxter

Manufacturers

B. Braun SEMedtronic PLC

Distributors Wholesalers

StrykerJohnson & Johnson

End Users

HospitalsSurgical CentersNursing Homes

Raw Material Suppliers

Johnson & JohnsonBaxter

Manufacturers

B. Braun SEMedtronic PLC

Distributors Wholesalers

StrykerJohnson & Johnson

End Users

HospitalsSurgical CentersNursing Homes

Hemostats - Supply Chain

Use Cases of Hemostats in Orthopedic Surgery & Cardiovascular Surgery

Orthopedic Surgery : The orthopedic surgery sector represents a primary market for hemostats because it generated 0.92 billion in revenue during 2024. The implementation of hemostats in orthopedic surgical procedures leads to decreased blood loss which results in better results for patients. The application of Oxidized Regenerated Cellulose Based Hemostats in orthopedic surgery benefits from their excellent absorbency properties and biocompatible nature. The market leaders Johnson & Johnson Services Inc. and Baxter maintain dominant positions through their development of specialized hemostat products which address specific requirements of orthopedic surgical procedures.

General Surgery : The general surgery field generated $0.67 billion in revenue during 2024 while using hemostats as a major application. The medical field uses Thrombin Based Hemostats because they provide fast bleeding control and effective results. B. Braun SE and Medtronic PLC lead the market through their development of advanced hemostat products which improve surgical performance and protect patient health.

Cardiovascular Surgery : The 2024 revenue of $0.40 billion from cardiovascular surgery depends on hemostats as a primary component. The medical field selects Combination Hemostats because they combine multiple active ingredients which provide enhanced benefits. Stryker leads the market through its development of advanced hemostatic products which help surgeons handle complicated cardiovascular surgical procedures.

Recent Developments

The medical and surgical field depends on hemostats as essential tools which have experienced major developments throughout the last few years. The global market for these vital tools expanded because of technological progress and rising surgical numbers and shifting medical practices toward less invasive procedures. The worldwide demand for hemostats continues to rise because surgical procedures increase globally. The market expansion of hemostats for surgical bleeding control has increased because of new technologically advanced products. The medical field has benefited from absorbable hemostats because they provide enhanced performance and safer treatment options for patients.

March 2025 : Johnson & Johnson Services Inc. introduced an enhanced hemostat product which adds to their existing hemostats range for the market.

December 2024 : Baxter established a sales agreement with a major healthcare organization to deliver its new hemostats which brought substantial growth to its customer network.

August 2024 : Medtronic PLC formed a joint venture with a biotech company to create and distribute advanced hemostats for market expansion purposes.

Impact of Industry Transitions on the Hemostats Market

As a core segment of the Medical Device industry, the Hemostats market develops in line with broader industry shifts. Over recent years, transitions such as Advanced Bioactive Hemostat Adoption and Shift Towards Minimally Invasive Surgeries have redefined priorities across the Medical Device sector, influencing how the Hemostats market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

Advanced Bioactive Hemostat Adoption

The shift toward bioactive and flowable hemostats is accelerating in the U.S. and Germany, driven by demand for faster coagulation, improved intraoperative efficiency, and reduced post surgical complications. This transition is reshaping procurement patterns across hospital networks and influencing adjacent segments such as surgical adhesives and wound closure solutions, where cross adoption of bioengineered materials is rising. With expanding integration into robotic surgeries and high acuity care settings, this trend is projected to contribute roughly $129 million in additional industry value by 2030, strengthening competitiveness across the regional medical device value chain.

Shift Towards Minimally Invasive Surgeries

The hemostats industry underwent a major change when surgeons began performing more minimally invasive surgical procedures. The ability of hemostats to manage bleeding in difficult to access small areas makes them essential for minimally invasive surgical procedures. The healthcare industry experienced a significant increase in minimally invasive surgical procedures worldwide because of this transition. The growing need for hemostats designed for minimally invasive procedures has driven product development and market direction changes.